← Eichor
Condition: Ibi363 Chemotherapy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Ibi363 Chemotherapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07408635Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07325630Study of IBI363 in Patients with Advanced First-line Gastric Cancer
Phase 1 · 1 location(s) · Xiangdong Cheng · NCT06610799IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage
Phase 2 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT07122687
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.